Education
About Us
Working with TipRanks
Follow Us
MindWalk Holdings (HYFT)
NASDAQ:HYFT
HYFT Stock Chart & Stats
$1.10
--
Market closed
$1.10
--
Day’s Range― - ―
52-Week Range$0.27 - $3.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)379.57K
Market Cap
$51.36M
Enterprise Value$57.65M
Total Cash (Recent Filing)$16.51M
Total Debt (Recent Filing)$3.63M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Mar 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding46,691,280
10 Day Avg. Volume315,704
30 Day Avg. Volume379,568
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.85
Price to Sales (P/S)0.83
P/FCF Ratio-2.80
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue2.81
Enterprise Value/Gross Profit5.14
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$5.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.24
Revenue Forecast (FY)$16.98M
Bulls Say, Bears Say
Bulls Say
Clinical Development And PartnershipsPlan to complete preclinical development and initiate a Phase 1 clinical study while seeking a development and commercial partner could accelerate clinical validation and support a faster pathway to market entry.
Financing Structure And Non-dilutive FundingCreation of Cayman Islands-based segregated portfolios to house AI-discovered candidates enables investors to fund single assets non-dilutively, providing targeted funding options for program advancement without broad shareholder dilution.
Vaccine Scientific PotentialDiscovery of a conserved functional constraint across influenza strains using HYFT Deep Data raises the prospect of a universal influenza vaccine that would reduce the need for frequent strain-specific updates and could reshape the global flu market if clinically validated and approved.
Bears Say
Competitive Landscape RiskIntense competition from established vaccine developers could limit market share and pricing power even if the company achieves clinical milestones.
Execution And Commercialization RiskCommercial challenges and execution failures could prevent promising programs from reaching market, undermining revenue prospects and investor returns.
Legal And Intellectual Property RiskExposure to legal issues and intellectual property disputes could delay development timelines, increase costs, or restrict the company’s ability to commercialize key assets.
MindWalk Holdings News
HYFT FAQ
What was MindWalk Holdings’s price range in the past 12 months?
MindWalk Holdings lowest stock price was $0.27 and its highest was $3.25 in the past 12 months.
What is MindWalk Holdings’s market cap?
MindWalk Holdings’s market cap is $51.36M.
When is MindWalk Holdings’s upcoming earnings report date?
MindWalk Holdings’s upcoming earnings report date is Mar 12, 2026 which is in 7 days.
How were MindWalk Holdings’s earnings last quarter?
MindWalk Holdings released its earnings results on Dec 15, 2025. The company reported -$0.051 earnings per share for the quarter, missing the consensus estimate of -$0.037 by -$0.015.
Is MindWalk Holdings overvalued?
According to Wall Street analysts MindWalk Holdings’s price is currently Undervalued.
Does MindWalk Holdings pay dividends?
MindWalk Holdings does not currently pay dividends.
What is MindWalk Holdings’s EPS estimate?
MindWalk Holdings’s EPS estimate is -0.04.
How many shares outstanding does MindWalk Holdings have?
MindWalk Holdings has 46,691,280 shares outstanding.
What happened to MindWalk Holdings’s price movement after its last earnings report?
MindWalk Holdings reported an EPS of -$0.051 in its last earnings report, missing expectations of -$0.037. Following the earnings report the stock price went up 1.13%.
Which hedge fund is a major shareholder of MindWalk Holdings?
Currently, no hedge funds are holding shares in HYFT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MindWalk Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (354.55% Upside)
$5.00 (354.55% Upside)
Blogger Sentiment
Bullish
HYFT Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
234.34%
12-Months-Change
Fundamentals
Return on Equity
-121.76%
Trailing 12-Months
Asset Growth
-56.69%
Trailing 12-Months
Company Description
MindWalk Holdings
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
HYFT Company Deck
HYFT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a generally positive outlook for MindWalk, with significant revenue growth, improved gross profit margins, and strategic initiatives like the divestiture of noncore operations and the launch of BioNative AI and HYFT technology. While there are challenges such as operating and net losses, the company's strong cash position and strategic focus on AI-driven R&D suggest a promising future.View all HYFT earnings summariesHYFT Stock 12 Month Forecast
Average Price Target
$5.00
▲(354.55% Upside)
Technical Analysis
XBiotech
―
Relmada Therapeutics
―
PMV Pharmaceuticals
―
Werewolf Therapeutics
―
Estrella Immunopharma
―
Ownership Overview
0.01% Insiders
0.03% Mutual Funds
0.06% Other Institutional Investors
99.89% Public Companies and
Individual Investors